Phase 2, Single-arm, Open-label, Study of Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Loncastuximab tesirine (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 22 Aug 2024 Planned number of patients changed from 39 to 100.
- 22 Aug 2024 Planned End Date changed from 1 Aug 2027 to 1 Aug 2030.
- 22 Aug 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Aug 2027.